24 October 2024 Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate.
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised. 25 October 2024
The US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines and recommends Capvaxive (pneumococcal 21-valent conjugate vaccine) for pneumococcal vaccination in adults 50 years of age and older. 25 October 2024
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Sanofi reported 15.7% sales growth for the third quarter of the year, reaching 13.4 billion euros ($14.2 billion), with adjusted earnings per share (EPS) rising by 12.2% to 2.86 euros, surpassing many forecasts. 25 October 2024
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' Kisqali (ribociclib). 24 October 2024
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 (20-valent pneumococcal conjugate vaccine) for all adults aged 50 and older. 24 October 2024
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
In 2016, the pharmaceutical industry based in Spain invested approximately 194 million euros ($219 million) in contracts with organizations and health professionals to further research and development (R&D) projects. 3 July 2017
Japanese drug majors Mitsubishi Tanabe Pharma and Daiichi Sankyo have been cleared to start selling Canalia, a combination therapy for type 2 diabetes, in Japan. 3 July 2017
The heart failure space across the seven key markets of the USA, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%. 3 July 2017
Teijin Pharma and French firm Ipsen have received approval from Japan’s medicines regulator to market Somatuline for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET). 3 July 2017
In a second deal with a pharma major in as many months, Exscientia, an innovative company at the forefront of artificial intelligence (AI)-driven drug discovery, has entered into a strategic drug discovery collaboration with GlaxoSmithKline. 3 July 2017
Takeda Pharmaceutical has selected three global CSR (corporate social responsibility) programs that emphasize prevention for health in developing and emerging countries. 3 July 2017
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) has welcomed the vote on the National Health Service (NHS) bill by the House of Representatives Plenum. 3 July 2017
Connecticut, USA-based biotech firm Cara Therapeutics has suffered a massive drop in share price after announcing disappointing top-line results from a Phase IIb study of its lead candidate CR845. 30 June 2017
The US Food and Drug Administration has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 30 June 2017
The US Food and Drug Administration has approved Triptodur (triptorelin) for the treatment of pediatric patients two years and older with central precocious puberty (CPP). 30 June 2017
The US non-profit organization the Institute for Clinical and Economic Review (ICER) has released a new report which finds little evidence to demonstrate that abuse-deterrent opioids have an impact on opioid abuse. 30 June 2017
The Australian government continues to make medicines available and more affordable for Australians with new listings worth A$142 million ($108 million) being added to the Pharmaceutical Benefits Scheme (PBS) from July 1, 2017. 30 June 2017
Daiichi Sankyo has announced top-line results from NEUCOURSE, a Phase III clinical trial in patients with post-herpetic neuralgia, and the ALDAY Phase III clinical trials in patients with fibromyalgia. 30 June 2017
Against a backdrop of ever-increasing requests for Orphan Drug designation in the USA, the Food and Drug Administration today unveiled a strategic plan to eliminate the agency’s existing backlog of requests and ensure continued timely response to all new requests for designation with firm deadlines. 29 June 2017
The interim president and chief executive of Teva Pharmaceutical, Yitzhak Peterburg, has said that he believes the healthcare industry is undergoing “huge disruption.” 29 June 2017
The European Commission today launched its new European Union action plan to tackle antimicrobial resistance (AMR) – a growing threat that is responsible for 25,000 deaths in the EU every year. 29 June 2017
UK-based Heptares Therapeutics, a wholly-owned subsidiary of Japan’s Sosei Group, and PeptiDream have entered into a strategic collaboration to discover, develop and commercialize novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases. 29 June 2017
Netherlands-headquartered independent drugmaker Norgine says the US Food and Drug Administration has accepted and will review the company’s regulatory submission for Plenvu. 29 June 2017
The US Federal Trade Commission is currently accepting public comments on an application by Grifols, a Spain-based manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was part of a 2011 FTC-ordered divestiture. 29 June 2017
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.